tetano
Editor, Senior Moderator
Vaccine. 2017 Feb 3. pii: S0264-410X(17)30082-8. doi: 10.1016/j.vaccine.2017.01.033. [Epub ahead of print]
[h=1]Efficacy of clade 2.3.2 H5 commercial vaccines in protecting chickens from clade 2.3.4.4 H5N8 highly pathogenic avian influenza infection.[/h] Yuk SS[SUP]1[/SUP], Erdene-Ochir TO[SUP]1[/SUP], Kwon JH[SUP]1[/SUP], Noh JY[SUP]1[/SUP], Hong WT[SUP]1[/SUP], Jeong JH[SUP]1[/SUP], Jeong S[SUP]1[/SUP], Gwon GB[SUP]1[/SUP], Shin JI[SUP]2[/SUP], Sur JH[SUP]2[/SUP], Song CS[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Emerging clade 2.3.4.4 of the highly pathogenic avian influenza (HPAI) virus strain H5N8, which had been detected sporadically in domestic poultry in China, started to affect wild birds and poultry in South Korea in 2014. The virus was spread to Germany, Italy, the Netherlands, United Kingdom, and even United States by migratory birds. Here, we tested currently used commercial clade 2.3.2 H5 vaccines to evaluate mortality, clinical signs, virus shedding, and histological damage after experimental infection of chickens with the clade 2.3.4.4 HPAI H5N8 virus. Although the vaccination protected chickens from death, it failed to prevent chickens from shedding the virus and from tissue damage according to histological examination. These results suggest that the use of appropriate vaccines that match the currently epidemic HPAI virus is recommended, and continuous HPAI surveillance and testing of currently used commercial vaccines should be performed.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Chicken; H5N8; Highly pathogenic avian influenza; Vaccine
PMID: 28169074 DOI: 10.1016/j.vaccine.2017.01.033
[PubMed - as supplied by publisher]
[h=1]Efficacy of clade 2.3.2 H5 commercial vaccines in protecting chickens from clade 2.3.4.4 H5N8 highly pathogenic avian influenza infection.[/h] Yuk SS[SUP]1[/SUP], Erdene-Ochir TO[SUP]1[/SUP], Kwon JH[SUP]1[/SUP], Noh JY[SUP]1[/SUP], Hong WT[SUP]1[/SUP], Jeong JH[SUP]1[/SUP], Jeong S[SUP]1[/SUP], Gwon GB[SUP]1[/SUP], Shin JI[SUP]2[/SUP], Sur JH[SUP]2[/SUP], Song CS[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Emerging clade 2.3.4.4 of the highly pathogenic avian influenza (HPAI) virus strain H5N8, which had been detected sporadically in domestic poultry in China, started to affect wild birds and poultry in South Korea in 2014. The virus was spread to Germany, Italy, the Netherlands, United Kingdom, and even United States by migratory birds. Here, we tested currently used commercial clade 2.3.2 H5 vaccines to evaluate mortality, clinical signs, virus shedding, and histological damage after experimental infection of chickens with the clade 2.3.4.4 HPAI H5N8 virus. Although the vaccination protected chickens from death, it failed to prevent chickens from shedding the virus and from tissue damage according to histological examination. These results suggest that the use of appropriate vaccines that match the currently epidemic HPAI virus is recommended, and continuous HPAI surveillance and testing of currently used commercial vaccines should be performed.
Copyright ? 2017. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Chicken; H5N8; Highly pathogenic avian influenza; Vaccine
PMID: 28169074 DOI: 10.1016/j.vaccine.2017.01.033
[PubMed - as supplied by publisher]